Advertisement


Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study

2024 ASH Annual Meeting

Advertisement

Hannah Choe, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, reviews results from a secondary analysis of the phase 2 AGAVE-201 study, which assessed axatilimab, an anti-colony stimulating factor 1 receptor monoclonal antibody, in the setting of chronic graft-versus-host disease (cGVHD). Dr. Choe reports on findings from the secondary analysis, which assessed the timing/dynamics of clinical and symptom responses in patients with cGVHD with axatilimab in AGAVE-201 (Abstract 98).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Agave 2.01 was an open label multicenter, randomized study of axatilimab at three different doses. This study met its primary endpoint with an NIH clinical response rate of 73% within the first six treatment cycles. It also met its key secondary endpoint with a seven point or more improvement in the modified Lee symptom scale of 55.1% of patients. In this analysis that we presented in the abstract at ASH 2024, we looked at those responders with NIH clinical response or mLSS symptom response. We evaluate the dynamics of these responses overall and by organ and also between the NIH clinical and symptoms scores. Responsive patients reflected the overall study population. There was heavy pre-treatment and also majority of patients with severe disease. The fastest responding organs by clinical responses were the upper GI tract, lower GI tract, joints, fascia, esophagus, and liver. With median responses seen 1.0 to 1.9 months. More than half of these responses were seen by day 56, if not day 84. The more fibrotic manifestations, which included the mouth, lungs, eyes, and skin, took longer to respond with median 2.1 to 3.2 months. But interestingly, we found that patients had symptom improvements as seen by improvements in their mLSS symptom scales faster with their NIH clinical responses in these slower responsive organs, including the mouth, lungs, and eyes, and trended towards significance with the skin. These responses were seen in the first one to two months. We now understand better how and when patients respond to axatilimab as assessed by clinicians with the NIH clinical response and patients from the patient reported outcomes from the modified Lee symptom scale. Importantly, patients responded with symptom improvements preceding that of the clinician, and this was seen particularly with the fibrotic manifestations, axatilimab, thus demonstrated rapid activity, not just by clinical responses, but also even more so with symptom responses sooner. And overall, it was well tolerated as seen in the overall AGAVE 201 study.

Related Videos

Hematologic Malignancies

Erik Thiele Orberg, MD, PhD, on Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined by Microbial Metabolite Profiles and Linked to Long-Term Outcomes

Erik Thiele Orberg, MD, PhD, of University Hospital Regensburg, shares findings of a longitudinal, prospective study investigating microbial and metabolite recovery in the post-transplant period. He discusses how these findings could have significant implications for future microbiome-modulating therapies, leading to improved long-term outcomes (Abstract 780).

Leukemia

Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL

Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Boston, discusses the primary endpoint evaluation of a phase II trial of the triplet regimen of acalabrutinib, venetoclax, and obinutuzumab in a population of patients with TP53-aberrrant chronic lymphocytic leukemia (CLL). The triplet was active and well tolerated as a front-line therapy, Dr. Davids noted, and these findings support its use for such patients with high-risk CLL (Abstract 1865).

Leukemia

Anne Sophie Michallet, MD, PhD, on MRD-Guided vs Standard Combination Therapy for Select Untreated Patients With CLL

Anne Sophie Michallet, MD, PhD, of Centre Léon Bérard Hospital, Lyon, France, discusses the final results of the phase II ERADIC trial (Abstract 584), which compared measurable residual disease (MRD)-guided therapy with ibrutinib and venetoclax with a standard combination regimen in patients with intermediate-risk chronic lymphocytic leukemia (CLL). Dr. Michallet also emphasizes the importance of defining the best patient profile for this MRD-guided combination given its potential for cardiologic toxicity.

Lymphoma

Timothy S. Fenske, MD, on Lack of Benefit of Autologous Hematopoietic Cell Transplantation in Mantle Cell Lymphoma Patients in First Complete Remission With Undetectable Minimal Residual Disease

Timothy S. Fenske, MD, of the Medical College of Wisconsin presented an initial report from the ECOG-ACRIN EA4151 phase III randomized trial exploring outcomes of autologous hematopoietic cell transplantation (ASCT) in mantle cell lymphoma. The researchers randomized patients in first complete remission with undetectable minimal residual disease and found that ASCT was not associated with improved outcomes (Abstract LBA-6).

Hematologic Malignancies

Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models

Jenny Paredes, PhD, of City of Hope National Medical Center, discusses a study investigating the effects of dietary fiber on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). The researchers evaluated a preclinical mouse model of GVHD with defined diet fiber concentrations and analyzed the dietary patterns of 173 allo-HCT patients (Abstract 259).

Advertisement

Advertisement




Advertisement